argenx to Present at Upcoming Investor Conferences
Rhea-AI Summary
argenx (Nasdaq: ARGX), a global immunology company, has announced its management team's participation in two upcoming investor conferences in September 2025. The company will present at the 2025 Wells Fargo Healthcare Conference on September 4 at 8:00 a.m. ET in Boston, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 7:00 a.m. ET in New York.
Investors can access live webcasts of both presentations through the Investors section of argenx's website, with replays available for approximately 30 days after each event.
Positive
- None.
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, ARGX declined 4.06%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. The stock closed at $679.19 on that trading session. This price movement removed approximately $1.83B from the company's valuation, bringing the market cap to $43.30B at that time.
Data tracked by StockTitan Argus on the day of publication.
August 28, 2025
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in September:
- 2025 Wells Fargo Healthcare Conference. Fireside chat on Thursday, September 4, 2025 at 8:00 a.m. ET in Boston, MA.
- Morgan Stanley 23rd Annual Global Healthcare Conference. Fireside chat on Monday, September 8, 2025 at 7:00 a.m. ET in New York, NY.
A live webcast of the presentations may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcasts will be available on the argenx website for approximately 30 days following the presentation.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Contacts
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
FAQ
When is argenx (ARGX) presenting at the Wells Fargo Healthcare Conference 2025?
What time is argenx's presentation at the Morgan Stanley Healthcare Conference 2025?
How can investors access argenx's (ARGX) conference presentations?
What type of company is argenx (ARGX)?
